LITESPARK-022

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Regulators cited LITESPARK-022 results showing reduced recurrence risk, with specific dosing and safety guidance issued.